Employer-Paid

Fifty-four percent of workers would give up at least one workplace perk for employer-covered GLP-1 treatment.

Stifel Financial violated the Employee Retirement Income Security Act by retaining two underperforming retirement plan funds, plaintiffs allege in a class-action lawsuit filed in U.S. District Court for the Eastern District of Missouri.

The framework links U.S. drug prices to international benchmarks through manufacturer agreements and federal pricing mechanisms, with major implications for high-cost drugs like GLP-1s.

For employers' health plans, the new ATTR-CM specialty drugs could cost $500,000 per participant treated.

A stop-loss market veteran looks at the differences between the two types of ERISA self-funded plans.

The move might, or might not, affect employers that fail to offer enough affordable major medical coverage.